LY4100511 + rabeprazole

LY4100511 + rabeprazole is a combination being studied to assess how rabeprazole, a proton pump inhibitor (PPI), influences the bioavailability and pharmacokinetics of LY4100511 (also known as DC-853), an investigational small molecule developed by Eli Lilly. This combination is not a marketed fixed-dose combination but an investigational regimen primarily used in bioavailability and drug-drug interaction studies in healthy participants. Rabeprazole acts by inhibiting gastric proton pumps, thereby reducing stomach acid production, which can affect the absorption of oral drugs like LY4100511. The mechanism of action of LY4100511 itself has not been disclosed in public trial records as of the current search, but rabeprazole's mechanism is established as an inhibitor of the gastric H+, K+-ATPase enzyme in parietal cells of the stomach.

Other names

LY4100511 + rabeprazoleDC-853 + rabeprazole